Detail akcie Renalytix AI Rg online

Business Summary: Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. KidneyIntelX, is a vitro diagnostic platform, employs a proprietary algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record or EHR, systems, to generate a patient risk score. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2025, Renalytix PLC revenues increased 31% to $3M. Net loss decreased 55% to $20.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects FV Adjustments of Financial Inves decrease of 89% to $400K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.42 to -$0.07.